Filing Flows › Iradimed (IRMD) › Guidance history
Iradimed (IRMD) guidance history: what it guided and what it reported
Iradimed gave guidance in 12 earnings releases on file since Feb 8, 2024. Of 8 guided periods since reported, it met or beat its own guidance 8 times (100%). Revenue: 8 of 8, on average +1.9% against the guided midpoint. Its releases raised guidance 3 times and lowered it once.
Revenue
Met or beat 8 of 8 periods (5 above, 3 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $25.0M–$26.5M (Oct 30, 2026) | — | to be reported | — |
| Q3 2026 | $23.0M–$24.5M (Aug 18, 2026) | $24.2M | within the range | +1.9% |
| Q2 2026 | $20.0M–$21.0M (May 1, 2026) | $20.5M | within the range | -0.2% |
| FY2026 | $91.0M–$96.0M (May 1, 2026) → lowered $91.6M–$93.1M (Oct 30, 2026) | — | to be reported | — |
| Q1 2026 | $21.0M–$22.0M (Feb 10, 2026) | $22.0M | within the range | +2.2% |
| Q4 2025 | $21.4M–$22.4M (Nov 3, 2025) | $22.7M | above the range | +3.6% |
| FY2025 | $80.0M–$82.5M (Aug 1, 2025) → raised $82.5M–$83.5M (Nov 3, 2025) | $83.8M | above the range | +1.0% |
| Q3 2025 | $20.5M–$20.9M (Aug 1, 2025) | $21.2M | above the range | +2.4% |
| Q2 2025 | $19.7M–$19.9M (May 5, 2025) | $20.4M | above the range | +3.1% |
| Q1 2025 | $19.2M–$19.4M (Feb 13, 2025) | $19.5M | above the range | +1.1% |
GAAP EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $0.53–$0.57 (Oct 30, 2026) | — | to be reported | — |
| Q3 2026 | $0.49–$0.54 (Aug 18, 2026) | — | — | — |
| Q2 2026 | $0.40–$0.44 (May 1, 2026) | — | — | — |
| Q1 2026 | $0.39–$0.43 (Feb 10, 2026) | — | — | — |
| FY2026 | $1.90–$2.05 (Feb 10, 2026) → reaffirmed $1.90–$2.05 (May 1, 2026) → reaffirmed $1.90–$2.05 (Aug 18, 2026) → lowered $1.90–$1.94 (Oct 30, 2026) | — | to be reported | — |
| Q4 2025 | $0.43–$0.47 (Nov 3, 2025) | — | — | — |
| Q3 2025 | $0.41–$0.45 (Aug 1, 2025) | — | — | — |
| Q2 2025 | $0.37–$0.40 (May 5, 2025) | — | — | — |
| Q1 2025 | $0.35–$0.39 (Feb 13, 2025) | — | — | — |
| FY2025 | $1.55–$1.65 (Feb 13, 2025) → reaffirmed $1.55–$1.65 (May 5, 2025) → raised $1.60–$1.70 (Aug 1, 2025) → raised $1.68–$1.72 (Nov 3, 2025) | — | — | — |
Stock-based compensation
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $2.0M (Feb 10, 2026) → raised $2.4M (May 1, 2026) → raised $2.5M (Aug 18, 2026) | — | to be reported | — |
| FY2025 | $2.6M (Feb 13, 2025) → reaffirmed $2.6M (May 5, 2025) → reaffirmed $2.6M (Aug 1, 2025) → lowered $2.4M (Nov 3, 2025) | — | — | — |
| FY2024 | $1.9M (Feb 8, 2024) → reaffirmed $1.9M (May 2, 2024) → reaffirmed $1.9M (Aug 1, 2024) → reaffirmed $1.9M (Oct 31, 2024) | — | — | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $0.57–$0.61 (Oct 30, 2026) | — | to be reported | — |
| Q3 2026 | $0.54–$0.59 (Aug 18, 2026) | — | — | — |
| Q2 2026 | $0.44–$0.48 (May 1, 2026) | — | — | — |
| Q1 2026 | $0.44–$0.48 (Feb 10, 2026) | — | — | — |
| FY2026 | $2.06–$2.21 (Feb 10, 2026) → reaffirmed $2.06–$2.21 (May 1, 2026) → raised $2.09–$2.24 (Aug 18, 2026) → lowered $2.07–$2.11 (Oct 30, 2026) | — | to be reported | — |
| Q4 2025 | $0.47–$0.51 (Nov 3, 2025) | — | — | — |
| Q3 2025 | $0.45–$0.49 (Aug 1, 2025) | — | — | — |
| Q2 2025 | $0.41–$0.44 (May 5, 2025) | — | — | — |
| Q1 2025 | $0.39–$0.43 (Feb 13, 2025) | — | — | — |
| FY2025 | $1.71–$1.81 (Feb 13, 2025) → reaffirmed $1.71–$1.81 (May 5, 2025) → raised $1.76–$1.86 (Aug 1, 2025) → raised $1.84–$1.88 (Nov 3, 2025) | — | — | — |
The latest quarter
Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%, net earnings $6.5M, operating cash flow $7.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does Iradimed beat its guidance?
Iradimed gave guidance in 12 earnings releases on file since Feb 8, 2024. Of 8 guided periods since reported, it met or beat its own guidance 8 times (100%). Revenue: 8 of 8, on average +1.9% against the guided midpoint.
How often does Iradimed raise guidance?
Its earnings releases raised guidance 3 times and lowered it once since Feb 8, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.